LONDON, June 21 (Reuters) - Shire Plc said on Thursday the U.S. Food and Drug Administration (FDA) intended to approve Intuniv, its extended-release, non-stimulant treatment for attention deficit ...

Medically reviewed by Patricia Mikula, PharmD Key Takeaways ADHD is often treated with medications and behavioral therapy. Stimulants are first-choice medications for children with ADHD. ADHD symptoms ...

Alembic is launching Guanfacine Extended-Release tablets in dosage strengths of 1 mg, 2 mg, 3 mg and 4 mg. The product is the generic of Takeda’s Intuniv Extended-Release tablets. Guanfacine ...

A federal judge on Tuesday certified a class of drug distributors and other companies who say they paid inflated prices for Shire PLC's ADHD drug Intuniv due to an improper patent lawsuit settlement ...